“Dramatic” Responses with Targeted Agent for Patients with CLL

VBCC - January 2013, Volume 4, No 1 - ASH Annual Meeting
Charles Bankhead

Atlanta, GA—Targeting Bruton’s tyrosine kinase (BTK) in patients with chronic lymphocytic leukemia (CLL) resulted in high response rates, without severe toxicity, according to the results of 2 studies that were presented at the 2012 American Society of Hematology meeting.

Data from one trial showed a 70% response rate in 116 patients treated with ibrutinib and a 22-month survival of 96% in previously untreated patients and 76% in the subgroup with relapsed/refractory CLL.

A second study reported at the meeting demonstrated objective responses in 83% of patients with high-risk CLL who were treated with ibrutinib.

“Ibrutinib has the potential to change the treatment landscape in CLL,” said John C. Byrd, MD, Director of Hematology at The Ohio State University Comprehensive Cancer Center in Columbus during a press conference.

BTK has emerged as a key player in the abnormal B-cell antigen receptor signaling that drives CLL and certain other B-cell diseases. Ibrutinib is one of several BTK inhibitors in development and is the farthest along in clinical investigation.

Dr Byrd presented results from a trial of ibrutinib monotherapy involving 85 patients with previously treated CLL and 31 treatment-naïve patients. All patients received 420 mg daily orally, which was associated with a 68% objective response rate (10% complete response [CR]) in the previously untreated patients and 70% (2% CR) in the relapsed/refractory group. In addition, 13% of the treatment-naïve patients and 4% of patients in the relapsed/refractory group had stable disease.

At 22 months, 96% of the treated sub­­group remained alive, as did 85% of the patients with relapsed/
refractory disease.

The second trial involved 40 patients with poor-prognosis CLL. The cohort included patients with a history of poor response to therapy and those with unfavorable genetics, said Jan Burger, MD, PhD, a hematologic oncologist at The University of Texas M.D. Anderson Cancer Center in Houston.
All patients received ibrutinib daily plus weekly infusions of rituximab during the first month, followed by once-monthly infusions thereafter. The regimen resulted in 1 CR, 32 partial responses, 2 minor responses, and no response in 2 patients. Two other patients had not been treated long enough for a response assessment.

Dr Burger characterized the ibrutinib- rituximab combination as highly active, not that several patients had particularly dramatic responses.
In both trials, ibrutinib was associated with low rates of severe toxicity. Dr Byrd reported a 13% incidence of grade 3/4 myelosuppression and grade 3/4 infection in 10% of untreated and 40% of relapsed/refractory patients.

Dr Burger reported 13 cases of grade 3/4 toxicity, including neutropenia, fatigue, pneumonia, insomnia, and bone pain.

Diarrhea was the most common adverse effect associated with ibrutinib in both trials, and cases were grade 1/2 in severity.

“Most side effects were modest and went away after the first couple of cycles of therapy,” noted Dr Byrd.
 

Related Items
Loss of Independence Common Even in Early-Stage Parkinson’s Disease
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Parkinson’s Disease
One-Fourth of Eligible Patients with Stroke Still Not Receiving Thrombolytic Therapy
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Stroke
Timing of Epilepsy Onset Influences Type of Cognitive Impairment and Memory Deficits
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Epilepsy/Seizures
Characteristics of “Superutilizers” Among Patients with Schizophrenia
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Schizophrenia
More Evidence of Increased Mortality Risk in Patients with Rheumatoid Arthritis
Charles Bankhead
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatoid Arthritis
Creatine Boosts Muscle in Rheumatoid Arthritis, but Not Strength or Function
Charles Bankhead
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Rheumatoid Arthritis
Mixed Cost Results with Repository Corticotropin Injection Therapy for Patients with SLE
Charles Bankhead
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Mutation Testing Encouraged for All Patients with Ovarian Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Personalized Medicine
Chemotherapy Use in Breast Cancer Declines with Gene-Based Assay
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Value in Oncology
Novel Regimen Outperforms Standard Chemotherapy in HER2 Breast Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Breast Cancer
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology